Clinical Cancer Research | 8/2017 Perioperative COX-2 and β-Adrenergic Blockade Improves Metastatic Biomarkers in Breast Cancer Patients in a Phase-II Randomized Trial

Oncotarget | 2017 Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study

OvidInsights | 9/2017 Validation of Lymphocyte-to-Monocyte Ratio as a Prognostic Factor in Advanced Pancreatic Cancer: An East Asian Cohort Study of 2 Countries

NEJM | 6/29/2017 Desmoid Tumors and Celecoxib with Sorafenib

KoreaMed Synapse | 3/2017 Perioperative administration of propranolol to women undergoing ovarian cancer surgery: A pilot study

Cancer | 8/24/2015 Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer

JAMA Dermatol | 9/16/2015 Growth Attenuation of Cutaneous Angiosarcoma With Propranolol-Mediated β-Blockade.

Cell | 9/10/2015 Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity

Ann Intern Med | 9/1/2015 Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drug Use and Colorectal Cancer Risk: A Population-Based, Case-Control Study.

Nature Reviews Cancer | 8/24/2015 Sympathetic nervous system regulation of the tumour microenvironment

Cancer| 8/24/2015 Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer

Cancer Med | 8/15/2015 A window-of-opportunity biomarker study of etodolac in resectable breast cancer

Cancers | 07/17/2015 Neural Regulation of Pancreatic Cancer: A Novel Target for Intervention

Cancers | 07/06/2015 Targeting NK-1 Receptors to Prevent and Treat Pancreatic Cancer: a New Therapeutic Approach

NEJM | 2/19/2015 A Randomized, Controlled Trial of Oral Propranolol in Infantile Hemangioma

J Clin Oncol  | GI ASCO January 2015 Effect of coadministered beta blocker and COX-2 inhibitor to patients with pancreatic cancer prior to receiving albumin-bound (Nab) paclitaxel.

J Clin Oncol | GI ASCO January 2015 Effect of coadministration of propranolol and etodolac (VT-122) plus sorafenib for patients with advanced hepatocellular carcinoma (HCC).

Cancer Immunol Immunothera | November 2014 A nervous tumor microenvironment: the impact of adrenergic stress on cancer cells, immunosuppression, and immunotherapeutic response

Science | 7/12/2013 Autonomic nerve development contributes to prostate cancer progression

NEJM | 10/25/2012 Aspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival

Cancer Prev Res | 8/5/2012 Effect of long-term propranolol treatment on hepatocellular carcinoma incidence in patients with HCV-associated cirrhosis

J Immununol | 1/1/2012 Regulation of Immune Responses by Prostaglandin E2

Drug Discovery Today: Therapeutic Strategies | Winter 2011 Adopting orphaned drugs: developing multidrug regimens using generic drugs

Arch Gynecol Obstet | December 2011 Effects of a selective COX-2 inhibitor in patients with uterine endometrial cancers

Nature Reviews Cancer | 9/23/2011 Perineural invasion and associated pain in pancreatic cancer.

JLB | May 2011 Propranolol as a modulator of M2b monocytes in severely burned patients.

Int J Cancer | 3/15/2010 Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion

J Immunol | 3/1/2010 Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a beta-adrenergic antagonist and a cyclooxygenase-2 inhibitor.

Nature Reviews Cancer | 3/1/2010 Eicosanoids and cancer

Ann Surg Oncol |  7/15/2008  Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis.